BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain
- Results show the drug is safe and well tolerated-JERUSALEM–(BUSINESS WIRE)–Sep 13, 2011 – BioLineRx (NASDAQ:BLRX) (TASE: BLRX) announced today the last visit of the lastsubject and preliminary results of the Phase Ia study of BL-1021,an…
September 13th, 2011
Posted in
Drug